.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

ESMO Virtual Congress 2020

Planchard, Pegram Review Evidence for Samsung Bioepis Biosimilars

September 22nd 2020

Article

Biosimilars from Samsung Bioepis have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists.

PrestigePharma Reports Positive PK Data for Bevacizumab Candidate

September 17th 2020

Article

Singapore-based PrestigePharma presents fresh equivalency data supporting its case for regulatory approval of HD201.

Positive Equivalency Data for a Trio of Biosimilars Are Reported

September 14th 2020

Article

Positive results emerging on oncology biosimilars will be presented at the European Society for Medical Oncology Virtual Congress 2020 this week .

Samsung Bioepis Reports Positive Phase 3 Results for Aybintio

September 14th 2020

Article

Samsung Bioepis' bevacizumab biosimilar demonstrates equivalence in analyses to be presented at the European Society for Medical Oncology Virtual Congress 2020.